Clinical Research Directory
Browse clinical research sites, groups, and studies.
COMPASS - COpenhagen MenoPAuSe Study
Sponsor: Martin Blomberg Jensen
Summary
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.
Official title: Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial
Key Details
Gender
FEMALE
Age Range
40 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
192
Start Date
2025-10-02
Completion Date
2028-05
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
Triptorelin 11.25 mg
Pamorelin 11.25 mg intramuscular injection once
Sodium Chloride 0.9%
Saline intramuscular injection once
Estradiol (E2)
Estreva gel 1.5 mg daily
Testosterone
Tostran gel 10 mg every other day
Placebo gel
Placebo gel every day or every other day
Locations (1)
Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.
Herlev, Denmark